ME/CFS Biomarkers: Expert Reaction to Blood Test Study
- This text presents a cautious and critical assessment of recent research claiming a new diagnostic tool for ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome).
- * Doesn't Identify Causes: The research identifies differences in DNA folding patterns in ME/CFS patients, but doesn't explain why these differences exist or what initially causes the condition.
- * Remarkably High Accuracy: A claimed 96% accuracy is unusually high for biomedical tests of this nature, making it a potentially overstated claim.
Summary of Dr. Miller’s Critique of the ME/CFS Research
This text presents a cautious and critical assessment of recent research claiming a new diagnostic tool for ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome). Here’s a breakdown of the key points raised by Dr. alastair Miller:
1. Limitations of the Research itself:
* Doesn’t Identify Causes: The research identifies differences in DNA folding patterns in ME/CFS patients, but doesn’t explain why these differences exist or what initially causes the condition. It only points to potential areas for further investigation.
* Statistical Uncertainty in Diagnostic Tool Performance: The reported 92% sensitivity (ability to correctly identify those wiht ME/CFS) is a statistical estimate with a wide range. It could realistically be as low as 73%, meaning a importent number of actual ME/CFS patients could receive a negative test result.
* Potential Biases in Study Design: The study’s methodology raises concerns about potential biases and limits the generalizability of the findings. Specifically:
* Data Source Issues: All ME/CFS cases came from a single source (LSHTM biobank), while controls were drawn from multiple sources, including a poorly defined “OBD repository.”
* Lack of Openness: The research paper lacks detail about the data sources, notably the OBD repository, raising questions about potential conflicts of interest (Oxford BioDynamics funded the research and employs most of the authors).
2. Concerns About the Diagnostic Tool’s Accuracy:
* Remarkably High Accuracy: A claimed 96% accuracy is unusually high for biomedical tests of this nature, making it a potentially overstated claim.
* Inadequate Control Group: The study used healthy controls,rather then individuals with other chronic conditions that share similar symptoms (like depression,fibromyalgia,or MS). this makes it arduous to determine if the test is truly specific to ME/CFS or simply differentiating between healthy individuals and those with any chronic illness.
3. Overall skepticism:
* Potential for “False Dawn”: Dr. Miller expresses concern that this research might potentially be another overhyped advancement that ultimately fails to deliver a reliable diagnostic tool, leading to unrealistic expectations for patients.
In essence,Dr. Miller urges caution, highlighting the need for more rigorous research with better controls and greater transparency before this diagnostic tool can be considered truly reliable or impactful. He emphasizes that while the research may be a starting point, it’s far from a definitive solution for diagnosing or understanding ME/CFS.